<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00858104</url>
  </required_header>
  <id_info>
    <org_study_id>IALT-07</org_study_id>
    <nct_id>NCT00858104</nct_id>
  </id_info>
  <brief_title>Percutaneous Laser Ablation in Benign Thyroid Nodules.Long Term Results</brief_title>
  <official_title>Multicentric Randomized Controlled Study of Percutaneous Laser Ablation Versus Follow Up in Benign Thyroid Nodules. Long Term Results</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Elesta S.R.L.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Elesta S.R.L.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Thyroid nodule pathologies occur frequently and represent a clinical issue for the
      endocrinologists, surgeons, nuclear physicians as well as the general practitioners. The
      incidence of this pathology has been further highlighted by the introduction of the
      ultrasound examination into the clinical practice as 20% with impalpable thyroid nodules is
      now detected through ultrasound. The majority of nodules are benign and characterized by slow
      growth, and therefore treated with suppressive doses of levothyroxine. Long-term
      levothyroxine treatment has, however, several well-known side effects and limitations.

      During the last years, number of controlled studies have demonstrated that ultrasound guided
      percutaneous laser treatment (PLA) is able to reach the target lesion within the thyroid with
      a high level of precision, and to destroy the thyroid tissue in a predictable and repeatable
      fashion, without side effects.

      Aim of the study:

        1. to assess 1-year and 3-year effect of laser ablation therapy on the volume of benign
           thyroid nodules and on nodule-related symptoms, and to compare these effects with
           findings in control group without active therapy;

        2. to assess the eventual re-occurence of thyroid lesions (observed after other types of
           ablation treatment, like percutaneous ethanol injection) during a 3-year follow-up;

        3. to demonstrate reproducibility of results within different environments and under
           different operators;

        4. to validate eventual presence of major or minor side effects.

      To this aim we shall randomized 200 patients either for PLA (100 pts) or standard follow-up.
      Patients will be recruited, treated and followed in 4 italian centers (Ospedale Regina
      Apostolorum - Roma, Arcispedale S. Maria Nuova - Reggio Emilia, Ospedale S. Maria della
      Misericordia - Perugia, Ospedale di Cisanello - Pisa) by physicians with experience in
      PLA.The scientific coordinator of this multicentre study is dr. Claudio Maurizio Pacella.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Short- (1-year) and long- (3-year) term evolution of the thyroid nodules volume and symptoms after the treatment vs. simple clinical observation.(Strong Endpoint: %nodules with greater than 50% base volume reduction and %patients free of symptoms)</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of short-term and long-term PLA safety, tolerability and reproducibility.</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>Thyroid Nodule</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Laser thermal ablation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Follow-up</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Percutaneous Laser Ablation</intervention_name>
    <description>Single session with standardized approach: Two fibers, up to 2 laser emissions; nodule volume up to 10 ml are treated by 800 Joules /ml and above 10 ml by 600 Joules/ml.The treatment is performed under local anesthesia and with diazepam sedation.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Arcispedale S. Maria Nuova is using commercially available system EchoLaser XVG</other_name>
    <other_name>(Integrated Ultrasound-Laser, Elesta, Italy). Other centers are using commercially available</other_name>
    <other_name>systems MyLab70XV (Ultrasound, Esaote, Italy) and Smart1064 BS (Nd:Yag Laser,</other_name>
    <other_name>DEKA, Italy). Disposable Fiber Optic devices : Bare Fiber PLA THY 2111, Bare Fiber PLA S</other_name>
    <other_name>(Asclepion Laser Technologies GmbH, Germany).</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The presence of a single nodule or dominating nodule;

          -  A solid or mixed echo-structure with less than 20% fluid volume;

          -  A lesion volume between 5 and 18 ml (greatest diameter &gt; 3.0 cm and &lt;= 4 cm);

          -  Thyroid hormone and TSH serum levels within the normalcy value;

          -  2 cytologically negative examinations for suspected neoplasia (British Thyroid
             Association, Second class THY)within the last six months;

          -  Calcitonin values within the normalacy value;

          -  Anticoagulant treatment suspension and antiaggregation treatment suspended for at
             least 72 hours.

        Exclusion Criteria:

          -  Hyperfunctioning lesion (99mTc scintigraph);

          -  Autoimmune thyreopathy or elevation of autoantibodies;

          -  Active anticoagulant treatment or antiaggregation treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Ospedale Regina Apostolorum</name>
      <address>
        <city>Albano Laziale</city>
        <state>Roma</state>
        <zip>00041</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera di Perugia - Osp. S.Maria della Misericordia</name>
      <address>
        <city>Perugia</city>
        <zip>06126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria di Pisa - Presidio di Cisanello</name>
      <address>
        <city>Pisa</city>
        <zip>56124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arcispedale S. Maria Nuova</name>
      <address>
        <city>Reggio Emilia</city>
        <zip>42100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Pacella CM, Bizzarri G, Guglielmi R, Anelli V, Bianchini A, Crescenzi A, Pacella S, Papini E. Thyroid tissue: US-guided percutaneous interstitial laser ablation-a feasibility study. Radiology. 2000 Dec;217(3):673-7.</citation>
    <PMID>11110927</PMID>
  </reference>
  <reference>
    <citation>Døssing H, Bennedbaek FN, Karstrup S, Hegedüs L. Benign solitary solid cold thyroid nodules: US-guided interstitial laser photocoagulation--initial experience. Radiology. 2002 Oct;225(1):53-7.</citation>
    <PMID>12354983</PMID>
  </reference>
  <reference>
    <citation>Pacella CM, Bizzarri G, Spiezia S, Bianchini A, Guglielmi R, Crescenzi A, Pacella S, Toscano V, Papini E. Thyroid tissue: US-guided percutaneous laser thermal ablation. Radiology. 2004 Jul;232(1):272-80. Epub 2004 May 20.</citation>
    <PMID>15155898</PMID>
  </reference>
  <reference>
    <citation>Døssing H, Bennedbaek FN, Hegedüs L. Effect of ultrasound-guided interstitial laser photocoagulation on benign solitary solid cold thyroid nodules - a randomised study. Eur J Endocrinol. 2005 Mar;152(3):341-5.</citation>
    <PMID>15757849</PMID>
  </reference>
  <reference>
    <citation>Papini E, Guglielmi R, Bizzarri G, Graziano F, Bianchini A, Brufani C, Pacella S, Valle D, Pacella CM. Treatment of benign cold thyroid nodules: a randomized clinical trial of percutaneous laser ablation versus levothyroxine therapy or follow-up. Thyroid. 2007 Mar;17(3):229-35.</citation>
    <PMID>17381356</PMID>
  </reference>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 6, 2009</study_first_submitted>
  <study_first_submitted_qc>March 6, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 9, 2009</study_first_posted>
  <last_update_submitted>May 23, 2014</last_update_submitted>
  <last_update_submitted_qc>May 23, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 26, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thyroid Diseases</mesh_term>
    <mesh_term>Thyroid Nodule</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

